RetaMaps

Columbia Endocrinology — Heidi Guzman, MD

CUIMC / Harkness Pavilion — Division of Endocrinology · 180 Fort Washington Ave Ste 904 · New York, NY 10032

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

Columbia University Irving Medical Center’s Division of Endocrinology is an academic hospital program for endocrine care, training, and research in diabetes, bone disease, neuroendocrine conditions, and weight control. Its Metabolic and Weight Control Center is a medical weight-management clinic staffed by board-certified endocrinologists; it uses diet, activity, behavioral support, and prescription weight-loss medication when appropriate and coordinates with Columbia’s bariatric surgery program. Adult care is delivered on the CUIMC campus in New York (including Harkness Pavilion / Fort Washington Avenue), with insurance billed when the plan covers visits. Official pages do not name specific GLP-1 brands.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsYes
Cash pay acceptedYes
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Clinicians

  • Heidi Guzman, MD

Nearby providers in New York City

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs